Genentech Logo
Banner Image

Avi Ashkenazi

Avi Ashkenazi
Avi Ashkenazi Director, Sr. Staff Scientist: Molecular Oncology

Profile | Education/Background | Top Scientific Papers | Awards & Honors

Top Scientific Papers

  • Herbst R, Eckhardt G, Kurzrock R, Ebbinghaus S, O'Dwyer P, Gordon M, Novotny W, Goldwasser M, Tohnya T, Lum B, Ashkenazi A, Jub A, Mendelson D. Phase I dose-escalation study of recombinant human (rh)Apo2L/TRAIL, a dual pro-apoptotic receptor agonist, in patients with advanced cancer. J Clin Onc (In press).

  • Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010 Feb 15; 16(4): 1256-63. View Abstract on PubMed

  • Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009 May 15; 137(4): 721-35. View Abstract on PubMed

  • Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009 May; 119(5): 1216-29. View Abstract on PubMed

  • Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009 Apr; 10(4): 348-55. View Abstract on PubMed

  • Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008 Dec; 7(12): 1001-12. View Abstract on PubMed

  • Jin H, Yang R, Ross J, Carano R, Fong S, Totpal K, Lawrence D, Zheng Z, Koeppen H, Schwall R, and Ashkenazi A. Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival. Clin Cancer Res 2008 Dec 1; 14(23): 7733-40. View Abstract on PubMed

  • Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008 June; 118(6): 1979-90. View Abstract on PubMed

  • Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008 Apr; 15(4): 751-61. View Abstract on PubMed

  • Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, Ashkenazi A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007 Dec 1; 110(12): 4037-46. View Abstract on PubMed

  • Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz S, Amler L, Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007 Sep; 13(9): 1070-7. View Abstract on PubMed

  • Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, Carano RA, Frantz GD, Tessier-Lavigne M, Bolon B, French DM, Ashkenazi A. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoSOne 6, e575, 2007. View Abstract

  • Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, Ashkenazi A. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ 2006 Oct; 13(10): 1619-30. View Abstract on PubMed

  • Kratz E, Eimon PM, Mukhyala K, Stern H, Zha J, Strasser A, Hart R, Ashkenazi A. Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ 2006 Oct; 13(10): 1631-40. View Abstract on PubMed

  • Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM, Klumperman J, Arnott D, Pham V, Scheller RH, Ashkenazi A. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A 2006 Jul 5; 103(27): 10283-8. View Abstract on PubMed

  • Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 Ligand/Tumor Necrosis Factor Related Apoptosis-Inducing Ligand. J Biol Chem 2005 Dec 9; 280(49): 40599-608. View Abstract on PubMed

  • Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005 Dec 2; 123(5): 931-44. View Abstract on PubMed

  • Sharp D, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE-inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005 May 13; 280(19): 19401-9. View Abstract on PubMed

  • Kelley R, Totpal K, Lindstrom S, Mathieu M, Billeci K, DeForge L, Pai R, Hymowitz S, Ashkenazi A. Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling. J Biol Chem 2005 Jan 21; 280(3): 2205-12. View Abstract on PubMed

  • Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A. Apo2L/TRAIL cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Canc Res 2004 Jul 15; 64(14): 4900-5. View Abstract on PubMed

  • Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004 Feb 20; 116(4): 491-7. View Abstract on PubMed

  • Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Erickson S, French D, Schow P, Grewal IS, Ashkenazi A. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004 Feb; 24(3): 997-1006. View Abstract on PubMed

  • Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002 Jun; 2(6): 420-30. View Abstract on PubMed

  • LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor—induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002 Mar; 8(3): 274-81. View Abstract on PubMed

  • Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, Ashkenazi A. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation the absence of caspase-8. J Biol Chem 2001 Dec 7; 276(49): 46639-46. View Abstract on PubMed

  • Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001 May; 7(5): 1362-9. View Abstract on PubMed

  • Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001 Apr; 7(4): 383-5. View Abstract on PubMed

  • Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000 Jun 29; 10(13): 785-8. View Abstract on PubMed

  • Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000 Jun; 12(6): 611-20. View Abstract on PubMed

  • Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999 Jul; 104(2): 155-62. View Abstract on PubMed

  • Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, Gray AM, Dowd AD, Brush AD, Heldens AD, Schow AD, Goddard AD, Wood WI, Baker KP, Godowski PJ, Ashkenazi A. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999 Feb 25; 9(4): 215-8. View Abstract on PubMed

  • Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998 Dec 17; 396(6712): 699-703. View Abstract on PubMed

  • Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998 Aug 28; 281(5381): 1305-8. View Abstract on PubMed

  • Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998 Apr 23; 8(9): 525-8. View Abstract on PubMed

  • Marsters S, Sheridan J, Pitti R, Gurney A, Skubatch M, Baldwin D, Huang A, Yuan J, Goddard A, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997 Dec 1; 7(12): 1003-6. View Abstract on PubMed

  • Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997 Aug 8; 277(5327): 818-21. View Abstract on PubMed

  • Marsters S, Skubatch M, Gray C, Ashkenazi A. Herpesvirus entry mediator, a novel member of the tumor necrosis factor receptor family, activates the NF-kB and AP-1 transcription factors. J Biol Chem 1997 May 30; 272(22): 14029-32. View Abstract on PubMed

  • Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996 May 31; 271(22): 12687-90. View Abstract on PubMed

  • Chamow SM, Ashkenazi A. Immunoadhesins: principles and applications [review]. Trends Biotechnol 1996 Feb; 14(2): 52-60. View Abstract on PubMed

  • Marsters S, Penica D, Bach E, Schreiber R, Ashkenazi A. Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci U S A 1995 Jun 6; 92(12): 5401-5. View Abstract on PubMed

  • Means R, Krantz S, Luna J, Marsters, S, Ashkenazi, A. Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon gamma receptor immunoadhesin. Blood 1994 Feb 15; 83(4): 911-5. View Abstract on PubMed

  • Barfod L, Zheng Y, Kuang W, Hart M, Evans T, Cerione R, Ashkenazi A. Cloning and expression of a human CDC42 GTPase Activating Protein reveals a functional SH3-binding domain. J Biol Chem 1993 Dec 15; 268(35): 26059-62. View Abstract on PubMed

  • Haak-Frendscho M, Marsters S, Chamow S, Peers D, Simpson N, Ashkenazi, A. Inhibition of interferon gamma by an interferon gamma receptor immunoadhesin. Immunology 1993 Aug; 79(4): 594-9. View Abstract on PubMed

  • Oksenberg D, Marsters A, O'Dowd B, Jin H, Havlik S, Peroutka S, Ashkenazi A. A single amino-acid difference confers major pharmacologic variation between human and rodent 5-HT1B receptors. Nature 1992 Nov 12; 360(6400): 161-3. View Abstract on PubMed

  • Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A 1991 Dec 1; 88(23): 10535-9. View Abstract on PubMed

  • Ashkenazi A, Presta L, Marsters S, Camerato T, Rosenthal K, Fendly B, Capon D. Mapping the CD4 binding site for human immunodefficiency virus type 1 by alanine-scanning mutagenesis. Proc Natl Acad Sci U S A 1990 Sep; 87(18): 7150-4. View Abstract on PubMed

  • Ashkenazi A, Ramachandran J, Capon DJ. Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic acetylcholine receptor subtypes. Nature 1989 Jul 13; 340(6229): 146-50. View Abstract on PubMed

  • Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functionally distinct G proteins couple different receptors to PI hydrolysis in the same cell. Cell 1989 Feb 10; 56: (3)487-493. View Abstract on PubMed

  • Ashkenazi A, Winslow J, Peralta E, Peterson G, Schimerlik M, Capon D, Ramachandran J. An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover. Science 1987 Oct 30; 238(4827): 672-5 View Abstract on PubMed

Book

  • Chamow, S, Ashkenazi, A, editors. Antibody Fusion Proteins. New York; John Wiley and Sons, Inc.; 1999.